Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer

Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology space, which is largely driven by interests and demands from the clinics for better solutions to target various hard-to-treat cancers. We discuss recent advances in various types of cell therapies, including T cell receptor-T cells, chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes and natural killer cells. Particularly, the present review focuses on the strategies to improve therapeutic responses by either enhancing tumor recognition or the resilience of infused immune cells within tumor microenvironment. Finally, we discuss the potential of other innate or innate-like immune cell types currently being explored as promising CAR-cell alternatives that seek to address the limitations of conventional adoptive cell therapies.

[1]  H. Ljunggren,et al.  Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia , 2022, Journal for immunotherapy of cancer.

[2]  Y. Liu,et al.  Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy , 2022, Science Translational Medicine.

[3]  Yanqi Yu,et al.  Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity , 2022, Cancers.

[4]  Hiu Ting Chan,et al.  Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy , 2022, Journal of translational medicine.

[5]  F. Marofi,et al.  Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction , 2022, Cancer cell international.

[6]  Baorui Liu,et al.  Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer , 2022, Human vaccines & immunotherapeutics.

[7]  C. Pan,et al.  CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy , 2022, Journal of experimental & clinical cancer research : CR.

[8]  Z. Berneman,et al.  Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells , 2022, Journal of Translational Medicine.

[9]  J. Thaxton,et al.  B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity , 2021, Journal for ImmunoTherapy of Cancer.

[10]  Dariusz M Plewczynski,et al.  PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress , 2021, Cancer Immunology Research.

[11]  Sagar M. Utturkar,et al.  Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells , 2021, Proceedings of the National Academy of Sciences.

[12]  Zhongen Wu,et al.  Targeting Wnt Signaling in the Tumor Immune Microenvironment to Enhancing EpCAM CAR T-Cell therapy , 2021, Frontiers in Pharmacology.

[13]  Chenya Wang,et al.  Coupling programmed cell death 1-positive tumor-infiltrating T cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy. , 2021, Cytotherapy.

[14]  G. Lucchini,et al.  CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial , 2021, Nature Medicine.

[15]  Chaoliang He,et al.  Localized Chemotherapy Based on Injectable Hydrogel Boosts the Antitumor Activity of Adoptively Transferred T Lymphocytes In Vivo , 2021, Advanced healthcare materials.

[16]  M. Ernstoff,et al.  Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors , 2021, Journal for ImmunoTherapy of Cancer.

[17]  W. Cho,et al.  A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers , 2021, Frontiers in Oncology.

[18]  Joseph C. Sun,et al.  Natural Killer Cells: From Innate to Adaptive Features. , 2021, Annual review of immunology.

[19]  A. Logan,et al.  KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. , 2021, Blood.

[20]  Ziyan Zhang,et al.  Coating with flexible DNA network enhanced T-cell activation and tumor killing for adoptive cell therapy , 2021, Acta pharmaceutica Sinica. B.

[21]  Rosalie M Sterner,et al.  CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.

[22]  Howard Y. Chang,et al.  Transient “rest” restores functionality in exhausted CAR-T cells via epigenetic remodeling , 2021, Science.

[23]  Xiaomei Wang,et al.  Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  G. Church,et al.  Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions , 2020, Journal of Hematology & Oncology.

[25]  Zhiyuan Niu,et al.  Chimeric antigen receptor‐modified macrophages trigger systemic anti‐tumour immunity , 2020, The Journal of pathology.

[26]  P. Hegde,et al.  Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. , 2020, Cancer discovery.

[27]  W. Wels,et al.  ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma , 2020, Frontiers in Immunology.

[28]  Tali Raveh-Sadka,et al.  Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis , 2020, Nature Medicine.

[29]  S. Galimberti,et al.  Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. , 2020, The Journal of clinical investigation.

[30]  K. Yasumoto,et al.  Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix , 2020, AntiCancer Research.

[31]  Jason S. Mitchell,et al.  Adoptive T Cell Therapy with IL-12–Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity , 2020, The Journal of Immunology.

[32]  F. Gao,et al.  CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. , 2020, Blood.

[33]  J. Schachter,et al.  Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia , 2020, Frontiers in Immunology.

[34]  M. Lotze,et al.  Oncolytic Virus Promotes Tumor-Reactive Infiltrating Lymphocytes for Adoptive Cell Therapy , 2020, Cancer Gene Therapy.

[35]  D. Kaufman,et al.  Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. , 2020, Cell stem cell.

[36]  Yao Huang,et al.  DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro , 2020, Cancer management and research.

[37]  Martha E. Zeeman,et al.  Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.

[38]  T. Barington,et al.  Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review , 2020, Frontiers in Immunology.

[39]  P. Thall,et al.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.

[40]  S. Asgharzadeh,et al.  Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages , 2020 .

[41]  E. Reinherz,et al.  Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display , 2019, Front. Immunol..

[42]  Huilan Wang,et al.  Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor , 2019, Front. Oncol..

[43]  Daofeng Liu,et al.  NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma , 2019, Clinical Cancer Research.

[44]  C. Klebanoff,et al.  T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance , 2019, Immunological reviews.

[45]  B. Solomon,et al.  Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression , 2019, Science Translational Medicine.

[46]  A. Zhu,et al.  Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells , 2019, Science Advances.

[47]  Xiaobo Xi,et al.  Magnetic Nanoclusters Armed with Responsive PD-1 Antibody Synergistically Improved Adoptive T-Cell Therapy for Solid Tumors. , 2019, ACS nano.

[48]  Bainan Liu,et al.  Target selection of CAR T cell therapy in accordance with the TME for solid tumors. , 2019, American journal of cancer research.

[49]  O. Lantz,et al.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells , 2018, Cell.

[50]  D. Kaufman,et al.  Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. , 2018, Cell stem cell.

[51]  H. Lokhorst,et al.  Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design , 2018, PloS one.

[52]  A. Eliseev,et al.  Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  Theresa Kaeuferle,et al.  Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia , 2018, Cancer Immunology, Immunotherapy.

[54]  Junnian Zheng,et al.  A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE , 2018, Cancer biology & therapy.

[55]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[56]  K. Gustafsson,et al.  Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[58]  A. Ashworth,et al.  Reprogramming human T cell function and specificity with non-viral genome targeting , 2017, bioRxiv.

[59]  A. Lundqvist,et al.  Correction to: Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma , 2017, Journal of Immunotherapy for Cancer.

[60]  Ping Chen,et al.  Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy , 2017, Journal of Translational Medicine.

[61]  J. Jansen,et al.  Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients , 2017, Clinical Cancer Research.

[62]  R. Brentjens,et al.  Adoptive T-Cell Therapy for Solid Tumors. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[63]  F. Claas,et al.  Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia , 2016, Science Translational Medicine.

[64]  M. Baker,et al.  Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. , 2016, The Journal of clinical investigation.

[65]  G. Roselli,et al.  Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model , 2016, Oncotarget.

[66]  L. Naldini,et al.  IFNα gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment , 2016, EMBO molecular medicine.

[67]  S. Grupp,et al.  Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies , 2016, Science Translational Medicine.

[68]  M. Sadelain,et al.  Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.

[69]  Alexandria P. Cogdill,et al.  Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. , 2015, Cancer research.

[70]  I. Pastan,et al.  Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1&agr;-secreting Glioblastoma , 2015, Journal of immunotherapy.

[71]  F. Locatelli,et al.  gd T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR- ab 1 /CD19 1 lymphocytes , 2016 .

[72]  K. Curran,et al.  Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[73]  Sadik H. Kassim,et al.  A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.

[74]  M. Brown,et al.  Mini Review Article , 2022 .

[75]  Hao Liu,et al.  Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. , 2014, Cancer research.

[76]  E. Andersson,et al.  A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma , 2014, Cancer Immunology, Immunotherapy.

[77]  M. Shokrgozar,et al.  T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy. , 2014, Biochimica et biophysica acta.

[78]  E. Seifried,et al.  Treatment of patients with advanced cancer with the natural killer cell line NK-92. , 2013, Cytotherapy.

[79]  B. Zhivotovsky,et al.  Doxorubicin sensitizes human tumor cells to NK cell‐ and T‐cell‐mediated killing by augmented TRAIL receptor signaling , 2013, International journal of cancer.

[80]  Jennifer G. Abelin,et al.  MHC Class I–Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia , 2013, Science Translational Medicine.

[81]  H. Okamura,et al.  Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells , 2013, Cancer Immunology, Immunotherapy.

[82]  E. Alici,et al.  Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. , 2012, Human gene therapy.

[83]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[84]  S. Eccles,et al.  Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling , 2012, Journal of Clinical Immunology.

[85]  Lei Zhang,et al.  Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer , 2012, Nature Medicine.

[86]  L. Moretta,et al.  Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. , 2011, Blood.

[87]  E. Oldfield,et al.  Indirect Stimulation of Human Vγ2Vδ2 T Cells through Alterations in Isoprenoid Metabolism , 2011, The Journal of Immunology.

[88]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  A. Amir,et al.  Mixed T cell receptor dimers harbor potentially harmful neoreactivity , 2010, Proceedings of the National Academy of Sciences.

[90]  T. Schumacher,et al.  Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy , 2010, Nature Medicine.

[91]  A. Seltsam,et al.  Permanent silencing of NKG2A expression for cell-based therapeutics , 2009, Journal of Molecular Medicine.

[92]  R. Negrin,et al.  In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. , 2008, Blood.

[93]  M. Caligiuri,et al.  Human natural killer cells. , 2008, Blood.

[94]  K. Nakagawa,et al.  Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. , 2008, Cytotherapy.

[95]  Hong Wang,et al.  Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens , 2007, Immunological reviews.

[96]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[97]  Y. Togashi,et al.  Critical role of the Th1/Tc1 circuit for the generation of tumor‐specific CTL during tumor eradication in vivo by Th1‐cell therapy , 2003, Cancer science.

[98]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[99]  T. Schumacher,et al.  Immunotherapy through TCR gene transfer , 2001, Nature Immunology.

[100]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[101]  L. Hood,et al.  Chimeric immunoglobulin-T cell receptor proteins form functional receptors: Implications for T cell receptor complex formation and activation , 1990, Cell.

[102]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[103]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.